2015 Annual Shareholder Meeting
Date: June 4, 2015
Time: 9:00 a.m. MDT
Renaissance Boulder Flatiron Hotel
500 Flatiron Blvd.
Broomfield, CO 80021
ARCA biopharma’s lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the prevention of atrial fibrillation (“AF”) in patients with heart failure and reduced left ventricular ejection fraction (“HFREF”) in a genetically defined subpopulation.